The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
P O Box 4171
West New York, NJ 07093 USA
The National Eosinophilia Myalgia Syndrome Network (NEMSN) is a non-profit organization founded in 1993 to help eosinophilia-myalgia syndrome (EMS) survivors and their families, as well as new patients suffering EMS-like symptoms. The 1989 EMS epidemic was associated with the ingestion of contaminated L-tryptophan supplements from one source, the Showa Denko company in Japan. The particular contaminant(s) that caused the EMS epidemic has not been definitely identified. In addition there is also evidence that a genetic predisposition is required for EMS onset. There are current cases of EMS and EMS-like disease. Patients have reported EMS-like symptoms after consuming L-tryptophan, as well as the chemically related 5-Hydroxytryptophan (5-htp) and Melatonin. EMS is a disease of abrupt onset causing severe, disabling, chronic muscle pain, skin symptoms and usually with high blood eosinophil levels. NEMSN offers patient education, networking and advocacy to patients worldwide through its website, www.nemsn.org. NEMSN also offers information and education to health professionals. The December 2019 NEMSN newsletter, at this link, contains the most up to date information on EMS as of the date of publishing. https://www.nemsn.org/sites/default/files/newsletters/December%202019.pdf
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.